Sage Journals: Discover world-class research

Abstract

Background

Retinal vasculopathy including retinal artery occlusion (RAO) or retinal vein occlusion (RVO) was recently found to occur more frequently in antiphospholipid syndrome (APS) patients than non-APS patients. This study aims to investigate the clinical manifestation and risk factors of retinal vasculopathy among APS patients.

Methods

In this single-center prospective cohort study, we evaluated APS patients with or without retinal vasculopathy during 2018–2020 at Peking Union Medical College Hospital. Clinical variables were compared, and a logistical regression model was built to explore risk factors. Hierarchical cluster analysis using Euclidean distances was applied to identify clusters of variables.

Results

A total of 310 APS patients (67.4% female, mean age 38.1 years) were included, of whom 18 (5.8%) were diagnosed with retinal vasculopathy (9 with RVO and 9 with RAO). No significant differences were found among most demographic characteristics, clinical manifestations, or antibody profiles. APS-related heart valve disease (odds ratio OR 13.66, 95% confidence interval CI 4.55–40.98), APS nephropathy (OR 12.77, 95% CI 4.04–40.35), and thrombocytopenia (OR 2.63, 95% CI 1.01–6.89) were predictive of retinal vasculopathy. APS-related heart valve disease and nephropathy were also found to be statistically significant predictors in multivariate logistical regression analysis. Non-criteria manifestations were aggregated with retinal vasculopathy from a cluster analysis of variables.

Conclusion

Patients with APS-related heart valve disease and nephropathy suffered a higher risk of retinal vasculopathy. The underlying mechanisms of aPL-associated retinal vasculopathy may involve thrombotic microangiopathy, leading to poor prognosis and therapeutic changes.

Keywords

Antiphospholipid syndrome retinal vasculopathy risk factor thrombotic microangiopathy

Get full access to this article

View all access options for this article.

References

Giordano

Senesi

Battisti

, et al. Antiphospholipid antibodies in patients with retinal vascular occlusions. Acta Ophthalmol Scand 1998; 76: 128–129.

Yehudai

Shoenfeld

Toubi

. Looking into the eyes of patients with antiphospholipid syndrome. Clin Rev Allergy Immunol 2007; 32: 192–197.

Demirci

Kucukkaya

Akarcay

, et al. Ocular involvement in primary antiphospholipid syndrome. Ocular involvement in primary APS. Int Ophthalmol 1998; 22: 323–329.

Akhlaghi

Abtahi-Naeini

Pourazizi

. Acute vision loss in systemic lupus erythematosus: bilateral combined retinal artery and vein occlusion as a catastrophic form of clinical flare. Lupus 2018; 27: 1023–1026.

Joshi

Afroz

Ranka

, et al. Bilateral central retinal artery occlusion from catastrophic antiphospholipid syndrome. BMJ Case Rep 2018: 2018: bcr2018226463. DOI: 10.1136/bcr-2018-226463.

Patel

Nguyen

. Central retinal vein occlusion: a review of current evidence-based treatment options. Middle East Afr J Ophthalmol 2016; 23: 44–48.

Hayreh

. Central retinal artery occlusion. Indian J Ophthalmol 2018; 66: 1684–1694.

Nishiguchi

Ito

Terasaki

. Bilateral central retinal artery occlusion and vein occlusion complicated by severe choroidopathy in systemic lupus erythematosus. Lupus 2013; 22: 733–735.

Chang

Chen

Lin

, et al. Combined central retinal artery and vein occlusion in a patient with systemic lupus erythematosus and anti-phospholipid syndrome. Lupus 2010; 19: 206–209.

10.

Zhou

Zhu

Wang

. Relationship between retinal vascular occlusions and incident cerebrovascular diseases: a systematic review and meta-analysis. Medicine (Baltimore) 2016; 95: e4075.

11.

Ermakova

Alekberova

Reshetniak

, et al. Retinal vascular lesions in systemic lupus erythematosus and secondary antiphospholipid syndrome. Vestn Oftalmol 2005; 121: 31–36.

12.

Janssen

den Heijer

Cruysberg

, et al. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost 2005; 93: 1021–1026.

13.

Franco

AMM

Medina

FMC

Balbi

GGM

, et al. Ophthalmologic manifestations in primary antiphospholipid syndrome patients: a cross-sectional analysis of a primary antiphospholipid syndrome cohort (APS-Rio) and systematic review of the literature. Lupus 2020; 29: 1528–1543.

14.

Utz

Tang

. Ocular manifestations of the antiphospholipid syndrome. Br J Ophthalmol 2011; 95: 454–459.

15.

Miyakis

Lockshin

Atsumi

, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.

16.

Gao

, et al. Retinal vasculopathy in patients with systemic lupus erythematosus. Lupus 2017; 26: 1182–1189.

17.

Gerkowicz

Latalska

Kosior-Jarecka

, et al. Antiphospholipid syndrome and changes in the eye. Klin Oczna 2005; 107: 143–146.

18.

Yang

Kruh

Foster

. Antiphospholipid antibody syndrome. Curr Opin Ophthalmol 2012; 23(6): 528–532.

19.

Yun

Kim

Lim

, et al. Case of catastrophic antiphospholipid syndrome presenting as neuroretinitis and vaso-occlusive retinopathy. BMC Ophthalmol 2020; 20: 482.

20.

Hong-Kee

Mei-Fong

Azhany

, et al. Antiphospholipid syndrome in lupus retinopathy. Clin Ophthalmol 2014; 8: 2359–2363.

21.

Cervera

Font

Gomez-Puerta

, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis 2005; 64: 1205–1209.

22.

Johnsen

Valborgland

Gudlaugsson

, et al. Thrombotic microangiopathy and the antiphospholipid syndrome. Lupus 2010; 19: 1569–1572.

23.

Kotzen

Roy

Jain

. antiphospholipid syndrome nephropathy and other thrombotic microangiopathies among patients with systemic lupus erythematosus. Adv Chronic Kidney Dis 2019; 26: 376–386.

24.

Tektonidou

. Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy. Clin Rev Allergy Immunol 2009; 36: 131–140.

25.

Daugas

Nochy

Huong

, et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol 2002; 13: 42–52.

26.

Nochy

Daugas

Droz

, et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol 1999; 10: 507–518.

27.

Kleinknecht

Bobrie

Meyer

, et al. Recurrent thrombosis and renal vascular disease in patients with a lupus anticoagulant. Nephrol Dial Transpl 1989; 4: 854–858.

28.

Mandal

Rathore

Douglas

. Catastrophic antiphospholipid syndrome presenting as dilated cardiomyopathy with bilateral branch retinal artery thrombosis. Int J Clin Pract 2000; 54: 550–551.

29.

Tenedios

Erkan

Lockshin

. Cardiac involvement in the antiphospholipid syndrome. Lupus 2005; 14: 691–696.

30.

Amigo

. What do we know about the cardiac valve lesion in the antiphospholipid syndrome (APS)? Lupus 2014; 23: 1259–1261.

31.

Rovere-Querini

Canti

Erra

, et al. Eculizumab in a pregnant patient with laboratory onset of catastrophic antiphospholipid syndrome: a case report. Medicine (Baltimore) 2018; 97: e12584.

32.

Abreu

Danowski

Wahl

, et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th international congress on antiphospholipid antibodies technical task force report on antiphospholipid syndrome clinical features. Autoimmun Rev 2015; 14: 401–414.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.04 MB

Characteristics and risk factors of retinal vasculopathy in antiphospholipid syndrome